Antithrombotic therapy for the treatment of venous thromboembolism.
VTE is a major but often-overlooked healthcare problem resulting in significant morbidity, mortality, and resource expenditures. The efficacy of anticoagulation therapy has been well documented in patients with The availability of LMWHs has advanced treatment of VTE by allowing for effective anticoagulation without the need for dose adjustments and routine monitoring. In addition, patients with uncomplicated DVT can be safely treated in the outpatient setting, allowing for shorter hospital stays and cost savings. LMWHs have been replacing traditional anticoagulants and are now considered the antithrombotic agents of choice in the initial treatment of VTE. Research on additional novel anticoagulants such as DTIs and factor Xa inhibitors is promising. These agents may offer potential benefits over current therapies, but their exact role in clinical practice remains to be determined pending additional ongoing clinical studies. Benefit-to-risk analyses will be necessary for determining how effective novel therapies will compare with established regimens.
Nutescu
Edith A
EA
Department of Pharmacy Practice, The University of Illinois at Chicago, College of Pharmacy, USA.
D000553:Ambulatory Care; D017850:Economics, Pharmaceutical; D004496:Education, Continuing; D005343:Fibrinolytic Agents / Q000191:economics / Q000627:therapeutic use*; D005569:Formularies as Topic; D006801:Humans; D017410:Practice Guidelines as Topic; D014481:United States; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology
D005343:Fibrinolytic Agents